top of page
LATEST NEWS
FDA Proposes One Approval for Many Mutations in Personalized Gene Editing
A new FDA draft guidance would let one license cover a personalized gene editor and its patient-specific versions. New mutations could be added with lab data instead of new clinical trials, a path built for cases like KJ Muldoon's.
3 days ago4 min read
Estuary Launches With $103 Million to Bring Gene Therapy to Polycystic Kidney Disease
Estuary Biotherapeutics launched with $103 million to develop one-time, kidney-directed AAV gene therapies for ADPKD, the most common inherited kidney disease. Here is how restoring polycystin proteins could stop, or even reverse, kidney cysts.
Oct 224 min read
Should Gene Therapy Be Used for Common Diseases? Two Cardiologists Propose Five Questions
One-time genetic treatments are moving from rare diseases to common ones like high cholesterol. In JAMA Internal Medicine, two University of Michigan cardiologists explain why permanence, rare side effects and cost call for a new framework.
Oct 224 min read
LEARN MORE
LEARN MORE
GENE TECH TIMES
The Future Has Arrived
Stem Cell Breakthrough Lets Paralyzed Patient Stand Again
Japanese researchers restored movement in a paralyzed man using reprogrammed stem cells injected into his spinal-cord injury. The treatment, tested in four patients, helped one man stand independently and another regain limb movement, offering early evidence that iPS cell therapies may support neural repair and future paralysis treatments.
Dec 3, 2025
Scientists Cure Type 1 Diabetes in Mice Using a Gentle Immune System “Reset”
Stanford Medicine researchers cured Type 1 diabetes in mice using a gentle immune-reset approach that combines donor blood stem cells and pancreatic islet transplants. The method prevented autoimmunity, required no immunosuppressive drugs, and may pave the way for future treatments for diabetes and other autoimmune diseases.
Dec 2, 2025
Vertex’s Stem Cell Therapy: A Bold Leap Toward a Type I Diabetes Cure
Vertex Pharmaceuticals has announced a pivotal milestone for its VX-880 therapy, a stem-cell-derived islet cell treatment to restore insulin production in people with type 1 diabetes (T1D). The treatment, which previously underwent a Phase 1/2 clinical trial, is now entering a Phase 1/2/3 trial, making it the first scalable T1D cure to reach this advanced stage. This combined trial streamlines the research process, integrating safety, efficacy, and confirmatory studies into a
Jan 13, 2025
Regenerating Hearts: How Stem Cell Therapy Could Transform the Treatment of Congenital Heart Diseases
Heart disease is a leading cause of death worldwide, affecting millions at every stage of life, including infants born with congenital heart defects. These conditions often result in a weakened heart, leading to symptoms such as chest pain, breathlessness, and swelling. If untreated, they can be fatal. While surgeries can offer temporary relief, many patients eventually face heart failure. They may require a heart transplant—a challenging solution due to the scarcity of donor
Nov 30, 2024
FDA Approves Stem Cell Therapy, Regenecyte, Shown to Help Chemotherapy Patients Recover Blood Count
The FDA has approved Regenecyte, an innovative therapy made from umbilical cord blood stem cells, to help rebuild blood and immune systems in patients with blood disorders or those recovering from intense treatments like chemotherapy. This breakthrough offers a promising option for patients needing healthy blood cell regeneration. Regenecyte uses stem cells collected from umbilical cords, which are highly adaptable and can grow into essential blood and immune cells. The treat
Nov 29, 2024
bottom of page